| P50 | author | Kay Seden | Q82805885 |
| P2093 | author name string | David M Burger | |
| | Sara Gibbons | |
| | Saye H Khoo | |
| | Catia Marzolini | |
| | Jonathan M Schapiro | |
| | David J Back | |
| P2860 | cites work | CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine | Q21034109 |
| | Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers | Q28367567 |
| | Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort | Q28477246 |
| | GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables | Q29547885 |
| | HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection | Q30392186 |
| | Prevalence of parasitemia and associated immunodeficiency among HIV-malaria co-infected adult patients with highly active antiretroviral therapy | Q33405425 |
| | Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. | Q33602047 |
| | Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration | Q33692808 |
| | Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid | Q33693946 |
| | Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy | Q33733033 |
| | Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria | Q33978975 |
| | Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children | Q34137766 |
| | Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity | Q34233691 |
| | In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation | Q34445138 |
| | Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. | Q34503553 |
| | Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers | Q34531724 |
| | Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis | Q35038647 |
| | Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications | Q35286119 |
| | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment | Q35583982 |
| | Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. | Q35598594 |
| | Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults | Q35692134 |
| | Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers | Q35771822 |
| | Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials | Q46327747 |
| | Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine | Q46691027 |
| | No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients | Q47875301 |
| | Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine | Q48006398 |
| | Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers | Q48705073 |
| | Hepatotoxicity Due to a Drug Interaction between Amodiaquine plus Artesunate and Efavirenz | Q56833699 |
| | Recognition of Risk for Clinically Significant Drug Interactions among HIV‐Infected Patients Receiving Antiretroviral Therapy | Q58858328 |
| | Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults | Q35829744 |
| | Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults | Q35883504 |
| | The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients | Q35906361 |
| | Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults | Q36144257 |
| | Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy | Q36290691 |
| | Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda | Q36298965 |
| | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults | Q36300127 |
| | Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults | Q36359372 |
| | Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers | Q36438820 |
| | Antiretroviral medication errors among hospitalized patients with HIV infection | Q36581552 |
| | Effect of malaria on HIV/AIDS transmission and progression | Q36588773 |
| | Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects | Q36715824 |
| | Epidemiology and burden of malaria in pregnancy | Q36717617 |
| | Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children | Q36739784 |
| | Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children | Q36876420 |
| | Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy | Q36951993 |
| | Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers | Q37364219 |
| | Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection | Q37623297 |
| | Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy | Q37688260 |
| | Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy | Q37811962 |
| | High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda | Q38876341 |
| | Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations | Q39119074 |
| | Population pharmacokinetics of mefloquine in patients with acute falciparum malaria | Q39465442 |
| | Malaria therapy in HIV: drug interactions between nevirapine and quinine | Q39544185 |
| | Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine | Q39753519 |
| | Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers | Q39972769 |
| | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients | Q41240864 |
| | Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications | Q41292997 |
| | Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients. | Q42249419 |
| | Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir | Q43124514 |
| | Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz | Q43229568 |
| | Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial | Q43418234 |
| | Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care | Q43488729 |
| | Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria | Q43855077 |
| | Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study | Q43867180 |
| | Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa | Q43932822 |
| | Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance | Q44024752 |
| | The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence. | Q44273051 |
| | In vitro metabolism of clindamycin in human liver and intestinal microsomes | Q44483232 |
| | Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. | Q45925838 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| | drug interaction | Q718753 |
| P304 | page(s) | e0173509 | |
| P577 | publication date | 2017-03-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection | |
| P478 | volume | 12 | |